ISIS PHARMACEUTICALS INC's ticker is ISIS and the CUSIP is 464330109. A total of 239 filers reported holding ISIS PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $41,197,000 | -32.4% | 1,019,236 | -3.8% | 0.02% | -26.7% |
| Q2 2015 | $60,979,000 | +0.3% | 1,059,580 | +10.9% | 0.03% | 0.0% |
| Q1 2015 | $60,818,000 | +11.9% | 955,196 | +8.5% | 0.03% | +7.1% |
| Q4 2014 | $54,351,000 | +86.1% | 880,326 | +17.1% | 0.03% | +75.0% |
| Q3 2014 | $29,203,000 | -43.6% | 752,077 | -50.0% | 0.02% | +14.3% |
| Q2 2014 | $51,818,000 | +59.5% | 1,504,154 | +100.0% | 0.01% | -22.2% |
| Q1 2014 | $32,497,000 | +8.5% | 752,077 | 0.0% | 0.02% | +5.9% |
| Q4 2013 | $29,962,000 | +9.9% | 752,077 | +3.5% | 0.02% | +6.2% |
| Q3 2013 | $27,273,000 | +110.0% | 726,482 | +50.3% | 0.02% | +100.0% |
| Q2 2013 | $12,987,000 | +36.4% | 483,296 | -14.0% | 0.01% | +33.3% |
| Q1 2013 | $9,520,000 | +76.4% | 562,014 | +46.5% | 0.01% | +50.0% |
| Q3 2012 | $5,397,000 | +16.1% | 383,610 | 0.0% | 0.00% | 0.0% |
| Q2 2012 | $4,649,000 | – | 383,610 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BB BIOTECH AG | 5,729,426 | $364,793,000 | 10.87% |
| DOWLING & YAHNKE LLC | 676,323 | $43,061,000 | 5.38% |
| WILLIAM HARRIS INVESTORS INC | 229,887 | $14,638,000 | 3.84% |
| Opus Point Partners Management, LLC | 60,912 | $3,878,000 | 3.25% |
| Nepsis Inc. | 64,580 | $4,112,000 | 2.48% |
| Private Capital Advisors, Inc. | 106,320 | $6,769,000 | 2.46% |
| PINNACLE ASSOCIATES LTD | 1,889,017 | $120,274,000 | 2.24% |
| MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ | 20,947 | $1,333,000 | 1.90% |
| Apex Capital Management | 928,654 | $59,127,000 | 1.39% |
| Bellevue Asset Management AG | 147,000 | $9,359,000 | 1.31% |